Catalent EBITDA 2012-2024 | CTLT

Catalent EBITDA for the quarter ending September 30, 2024 was $0.046B, a 107.49% decline year-over-year.

  • Catalent 2024 EBITDA was -0.246B, a 192.13% decline from 2023.
  • Catalent 2023 EBITDA was 0.267B, a 76.05% decline from 2022.
  • Catalent 2022 EBITDA was 1.115B, a 1.15% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Catalent EBITDA 2012-2024 | CTLT

  • Catalent 2024 EBITDA was -0.246B, a 192.13% decline from 2023.
  • Catalent 2023 EBITDA was 0.267B, a 76.05% decline from 2022.
  • Catalent 2022 EBITDA was 1.115B, a 1.15% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.1B
Takeda Pharmaceutical (TAK)$45.2B
Merck (MKKGY)$21.6B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$19.9B
United Therapeutics (UTHR)$17.1B
Summit Therapeutics (SMMT)$15B
Shionogi (SGIOY)$12.6B
Neurocrine Biosciences (NBIX)$12.3B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.5B
Crinetics Pharmaceuticals (CRNX)$4.6B
PTC Therapeutics (PTCT)$3.1B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
Ocular Therapeutix (OCUL)$1.6B
Harrow (HROW)$1.6B
Evotec AG (EVO)$1.6B
Xencor (XNCR)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B
BioCryst Pharmaceuticals (BCRX)$1.5B